Influence of Human Sera on the In Vitro Activity of the Echinocandin Caspofungin (MK-0991) against Aspergillus fumigatus
- 1 December 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (12), 3302-3305
- https://doi.org/10.1128/aac.44.12.3302-3305.2000
Abstract
There have been several reports that the activity of echinocandin antifungal agents is not affected or decreased in the presence of human sera. It is known that these drugs are bound >80% in animal and human sera. The activity of the echinocandin caspofungin (MK-0991), a 1,3-β- d -glucan synthase inhibitor, against Aspergillus fumigatus with and without human sera was studied. Conidia of A. fumigatus in microtest plate wells formed germlings after overnight culture in RPMI 1640. Caspofungin was then added with or without serum, and the germlings were incubated at 37°C for 24 h. Human serum (5%) in RPMI 1640 alone did not significantly inhibit the growth of A. fumigatus in vitro. Caspofungin in RPMI 1640 exhibited dose-dependent inhibition, with concentrations of 0.1 and 0.05 μg/ml inhibiting 24.9% +/− 10.4% and 11.7% +/− 3.6%, respectively ( n = 10; P < 0.01). The addition of 5% human serum to caspofungin at 0.1 or 0.05 μg/ml increased the inhibition to 78.6% +/− 5.8% or 58.3% +/− 19.2%, respectively ( n = 10; P < 0.01 versus controls and versus the drug without serum). Lower concentrations of serum also potentiated drug activity. The effect of human sera was further seen when using caspofungin that had lost activity (e.g., by storage) against A. fumigatus at 0.1 μg/ml. Inactive caspofungin alone demonstrated no significant inhibition of hyphal growth, whereas the addition of 5% human serum to the inactive drug showed 83% +/− 16.5% inhibition ( n = 5; P < 0.01). The restoration of activity of caspofungin was seen at concentrations as low as 0.05% human serum. In contrast to prior reports, this study suggests that human serum acts synergistically with caspofungin to enhance its inhibitory activity in vitro against A. fumigatus .Keywords
This publication has 8 references indexed in Scilit:
- Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus.Journal of Antimicrobial Chemotherapy, 1999
- Activity of Voriconazole Combined with Neutrophils or Monocytes against Aspergillus fumigatus : Effects of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating FactorAntimicrobial Agents and Chemotherapy, 1998
- Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum.Mycopathologia, 1998
- In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)Antimicrobial Agents and Chemotherapy, 1997
- Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosisAntimicrobial Agents and Chemotherapy, 1997
- Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)Antimicrobial Agents and Chemotherapy, 1997
- Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activityAntimicrobial Agents and Chemotherapy, 1995
- A Simplified New Assay for Assessment of Fungal Cell Damage with the Tetrazolium Dye, (2,3)-bis-(2-Methoxy-4-Nitro-5-Sulphenyl)-(2H)-Tetrazolium-5-Carboxanilide (XTT)The Journal of Infectious Diseases, 1995